TriangleHEALTH PROFESSIONAL · SOURCE READING
Classical Hodgkin lymphoma, intermediate-risk disease
Source: Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 16, 2025 · Captured 2026-09-09.
Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.
Table 8 summarizes the results of treatment approaches used for pediatric patients with intermediate-risk Hodgkin lymphoma.
Source links and citations
| Chemotherapy (No. of Cycles)a | Radiation (Gy) | Stage | No. of Patients | Event-Free Survival Rate (No. of Years of Follow-up) | Survival Rate (No. of Years of Follow-up) |
|---|---|---|---|---|---|
| CR = complete response; CS = clinical stage; E = extralymphatic; IFRT = involved-field radiation therapy; N/A = not applicable; RER = rapid early response; SER = slow early response. | |||||
| aFor more information about the chemotherapy regimens, see Table 6. | |||||
| OEPA (2) + COPDAC (2) [22] | IFRT (20–35) | IE, IIB, IIEA, IIIA | 139 | 88.3% (5) | 98.5% (5) |
| ABVE-PC (3–5) [21] | IFRT (21) | IIA/IIIA, if bulky disease | 53 | 84% (5) | 95% (5) |
| ABVE-PC: RER/CR [20] | IFRT (21) | IB, IAE, IIB, IIAE, IIA, IVA, IA, IIA + bulky disease | 380 | 87.9% (4) | 98.8% (4) |
| ABVE-PC: RER/CR [20] | None | IB, IAE, IIB, IIAE, IIA, IVA, IA, IIA + bulky disease | 382 | 84.3% (4) | 98.8% (4) |
| ABVE-PC: SER: +DECA [20] | IFRT (21) | IB, IAE, IIB, IIAE, IIA, IVA, IA, IIA + bulky disease | 153 | 79.3% (4) | 96.5% (4) |
| ABVE-PC: SER: -DECA [20] | IFRT (21) | 151 | 75.2% (4) | 94.3% (4) | |
Publication references
Read the original reference and check its publication notices.
Preserved source evidence · Not medical advice